menu
    • menu

    Company profile for Ionis Pharmaceuticals

    NEW Drugs in Dev: 64
    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-03-23

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    Quotient Sciences- Molecule to Cure. Fast.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Ionis PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    2855 Gazelle Court Carlsbad, CA 92010
    Telephone
    Telephone
    760-931-9200
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.ionispharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ionis-pharmaceuticals
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/ionispharma?lang=en

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    Asia Pharma Expo

    Not Confirmed

    envelop Contact Supplier

    Asia Pharma Expo

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Ionis Slashes Tryngolza's Price Ahead Of Planned Label Expansion
    Ionis Slashes Tryngolza's Price Ahead Of Planned Label Expansion

    25 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/ionis-slashes-tryngolzas-price-tag-down-ahead-anticipated-expansion-wider-shtg-market

    FIERCE PHARMA
    25 Mar 2026
    Share Share
    Ionis NDA For Zilganersen Gets FDA Priority Review
    Ionis NDA For Zilganersen Gets FDA Priority Review

    23 Mar 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260323790940/en/Ionis-announces-zilganersen-New-Drug-Application-for-Alexander-disease-AxD-accepted-by-FDA-for-Priority-Review

    BUSINESSWIRE
    23 Mar 2026
    Share Share
    Ionis Announces Changes To Board Of Directors
    Ionis Announces Changes To Board Of Directors

    09 Mar 2026

    // BUSSINESSWIRE

    https://www.businesswire.com/news/home/20260309350880/en/Ionis-announces-changes-to-Board-of-Directors

    BUSSINESSWIRE
    09 Mar 2026
    Share Share
    Ionis To Present New Data On DAWNZERA In Hereditary Angioedema
    Ionis To Present New Data On DAWNZERA In Hereditary Angioedema

    27 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260227946756/en/Ionis-to-present-new-data-supporting-DAWNZERA-donidalorsen-in-hereditary-angioedema-at-2026-AAAAI-Annual-Meeting

    BUSINESSWIRE
    27 Feb 2026
    Share Share
    FDA Grants Priority Review to Olezarsen sNDA for Severe HTG
    FDA Grants Priority Review to Olezarsen sNDA for Severe HTG

    26 Feb 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260226109569/en/Olezarsen-sNDA-accepted-by-the-FDA-for-Priority-Review-for-the-treatment-of-severe-hypertriglyceridemia-sHTG

    BUSINESSWIRE
    26 Feb 2026
    Share Share
    Ionis Reveals 2025 Financial Results And Program Advancements
    Ionis Reveals 2025 Financial Results And Program Advancements

    25 Feb 2026

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2026-02-25/ionis-reports-fourth-quarter-and-full-year-2025-financial-results-and-highlights-progress-on-key-pro

    PHARMIWEB
    25 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact Ionis Pharmaceuticals and get a quotation

    Ionis Pharmaceuticals is a supplier offers 1 products (APIs, Excipients or Intermediates).

    Find a price of Nusinersen bulk offered by Ionis Pharmaceuticals

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search